The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Proteomic profiling of circulating tumor cells (CTCs) in metastatic urothelial cancer (mUC) as associated with upregulation of EGFR, HER2, and B7-H3 in patients (pts) progressing on enfortumab vedotin (EV) plus pembrolizumab.
 
Wadih Issa
No Relationships to Disclose
 
Navneet Kaur
No Relationships to Disclose
 
Qinhan Zhou
No Relationships to Disclose
 
Ze Yu
No Relationships to Disclose
 
Shahed Abdullah
No Relationships to Disclose
 
Libin Yan
No Relationships to Disclose
 
Chao Xing
No Relationships to Disclose
 
Suzanne Cole
Research Funding - Merck (Inst)
 
Changchuan Jiang
Honoraria - MJH Life Sciences
 
Qian Qin
Honoraria - MashupMedia; MJH Life Sciences
Consulting or Advisory Role - Eisai; Exelixis; Janssen
Research Funding - Exelixis; Janssen
 
Jue Wang
No Relationships to Disclose
 
Kevin Courtney
Honoraria - Curio Science
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Celgene/Bristol-Myers Squibb (Inst); DualityBio (Inst); Exelixis (Inst); FibroGen (Inst); Harpoon therapeutics (Inst); Janssen Research & Development (Inst); Lilly (Inst); Myovant Sciences (Inst); Novartis (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Surface Oncology (Inst)
Patents, Royalties, Other Intellectual Property - My spouse receives patent royalties from Athena Diagnostics, Inc. (I)
 
Andrew Wang
Leadership - Archimmune Therapeutics; Capio BioSciences; Immune-X
Stock and Other Ownership Interests - Archimmune Therapeutics; Archimmune Therapeutics; Capio BioSciences
Consulting or Advisory Role - Aptitude Health (I); Aravive (I); AVEO (I); Bayer (I); Capio BioSciences; Dendreon (I); Eisai (I); Gerson Lehrman Group; Janssen (I); Johnson & Johnson Innovation; Kidney Cancer Association (I); Merck KGaA (I); Mirati Therapeutics (I); MJH Associates (I); Peerview (I); PlatformQ Health (I); QED Therapeutics (I); Regeneron (I); Sanofi/Aventis (I); Seagen (I)
Research Funding - Archimmune Therapeutics; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Antigen capturing nanoparticles technology licensed to Archimmune Therapeutics; Biomatrix patent licensed to PhoenixSongs
Travel, Accommodations, Expenses - Exelixis (I); Genentech (I); Pfizer (I); Sanofi (I)
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; Dava Oncology; Mashup Media; MJH Life Sciences; Peerview
Consulting or Advisory Role - AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Dendreon; Eisai; EMD Serono; Exelixis; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Loxo/Lilly; Merck; Novartis; Pfizer; Xencor
Research Funding - ALX Oncology (Inst); Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Janux Therapeutics (Inst); Kura Oncology (Inst); Loxo/Lilly (Inst); Merck (Inst); OncoC4; Pfizer (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Bayer; Janux Therapeutics; Johnson & Johnson/Janssen
Other Relationship - ASCO; Kidney Cancer Association; KidneyCan; Myrovlytis Trust; Winn Foundation